Hyperferritinemia in ovarian cancer.

Area of Science:

• Oncology
• Biochemistry
• Gynecology

Background:

• Ovarian cancer is a leading cause of cancer-related death in women.
• Early detection and accurate tumor markers are crucial for improving patient outcomes.
• Serum ferritin's role in ovarian cancer has not been fully elucidated.

Purpose of the Study:

• To investigate the association between elevated serum ferritin and ovarian cancer.
• To evaluate the potential of serum ferritin as a tumor marker for ovarian cancer.
• To analyze ferritin levels in relation to disease characteristics, including liver metastases.

Main Methods:

• A prospective study involving 50 women with ovarian cancer.
• Inclusion of control groups: 116 healthy volunteers, 51 patients with benign gynecologic tumors, and 15 with benign liver disease.
• Measurement of serum ferritin levels using standardized assays.

Main Results:

• Mean serum ferritin levels were significantly higher in ovarian cancer patients (436.7 ng/mL) compared to controls.
• Hyperferritinemia (elevated ferritin) was present in 50% of ovarian cancer patients.
• Marked increases in ferritin were observed in patients with liver metastases; 21.4% elevation in epithelial carcinoma without hepatic involvement.

Conclusions:

• Elevated serum ferritin is significantly associated with ovarian cancer.
• Serum ferritin demonstrates potential as a tumor marker for ovarian cancer, especially in cases with liver involvement.
• Further research is warranted to establish serum ferritin's clinical utility in ovarian cancer diagnosis and management.